merk

Merck Acquires Rigontec for $550 Million

Merck Acquires Rigontec for $550 Million

Merck & Co. Inc. (NYSE: MRK) announced today its acquisition of German biotech start-up, Rigontec for approximately €464 million or $550 million to further advance studies and research in cancer treatment development.Merck agreed to pay &eu..